Keith Woods
Known title: Chief Operating OfficerCIK: 0001996804
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround. X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.
Transaction History
| SRRK | ▼ Sell | Gift | 48,034 | $0 | 9/24/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 10,220 | $507K | 4/16/2026 | View on chart |
| SRRK | ▲ Buy | Grant | 47,021 | $0 | 2/9/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 16,746 | $715K | 1/13/2026 | View on chart |
| XFOR | ▲ Buy | Grant | 1,500 | $0 | 6/9/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 100,000 | $0 | 4/27/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 500,000 | $0 | 4/27/2025 | View on chart |
| XFOR | ▲ Buy | Grant | 45,000 | $0 | 6/10/2024 | View on chart |
| XFOR | ▲ Buy | Grant | 90,000 | $0 | 10/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA
Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.